Pulmonary Hypertension News Forums Forums Research and Development Did you miss our top three read articles in May?

  • jsexton

    Member
    June 21, 2024 at 7:58 am

    What I found very interesting is that a lot of the new research is based on the “blocking” properties. Seralutinib, WinRevair and others in the pipeline look to be going after how can we block all these PH things from happening. Very interesting read. I can tell you in doing my research for 12 years with PH, you really have to use the Webster to understand more! lol Very good read! Thanks for shareing!

  • Deleted User

    Member
    July 18, 2024 at 11:19 pm

    Absolutely, the focus on “blocking” properties in new research is indeed fascinating. Seralutinib, WinRevair, and other treatments in the pipeline are targeting specific pathways to prevent the progression of pulmonary hypertension (PH). The advancements in this area are impressive and show how far we’ve come in understanding PH. With 12 years of research under your belt, it’s clear how complex and detailed this field can be—sometimes it feels like you need a dictionary just to keep up! I also found the article on CardioBalance – Hypertension very informative. Thanks for sharing your insights and experience! For hypertension & heralth supplements check https://thenaturemeds.com.

Log in to reply.